LABP

Landos Biopharma, Inc.

5.27 USD
-1.02 (-16.22%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Landos Biopharma, Inc. stock is up 14.32% since 30 days ago. The next earnings date is Mar 21, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 3 February’s closed higher than January.

About Landos Biopharma, Inc.

Landos Biopharma, Inc. discovers and develops oral therapeutics for patients with autoimmune diseases. The company's lead product candidate in development include omilancor, a gut-restricted oral therapeutic candidate that targets lanthionine synthetase C-like protein 2 (LANCL2) for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and eosinophilic esophagitis.